The Irish Times covered the MERLIN Project on April 22nd, 2014, in an article titled “Orbsen Therapeutics to take part in €6m liver disease clinical trial.”
Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (Remedi) has announced plans to partner with the University of Birmingham in a €6 million project to fight liver disease.
The stem cell research company, which was founded by Prof Frank Barry and Prof Tom O’Brien in 2006, will collaborate with the university on an EU FP7-funded project known by as Merlin (MEsynchymal stem cells to Reduce Liver INflammation). The project, which is led by Prof Phil Newsome, will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial.
Please read the rest of the article here.
MERLIN partners meet in Birmingham, UK, on 10-11 February, 2014 to initiate the project.
The MERLIN project website is now launched. This website will support individuals trying to find out more about the project, and will provide both the public and other researchers with information about our plans, hypotheses, work and results.
- RT @LongerLifeOrg: Nonalcoholic fatty liver disease is the only liver disease with growing prevalence in the U.S. in the last 30 years. Epi… Time ago 26 Days via Twitter for iPhone
- RT @AutoImmuneLiver: Stay conmected with patient support groups @PSCSupportUK @PSCPartners to keep up with progress. Cure is a challenge bu… Time ago 134 Days via Twitter Web Client
- RT @nephstrom: JUST OUT! A new #OpenAccess @nephstrom publication in @FrontImmunol from our partners at @Istituto di Ricerche Farmacologich… Time ago 134 Days via Twitter Web Client
Follow @fp7merlin on twitter.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.